NCT01469338View on ClinicalTrials.gov

Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel

PHASE2TerminatedINTERVENTIONAL
Enrollment

9

Participants

Timeline

Start Date

July 31, 2012

Primary Completion Date

October 31, 2014

Study Completion Date

November 30, 2014

Conditions
DiarrheaHormone-resistant Prostate CancerRecurrent Prostate CancerStage I Prostate CancerStage IIA Prostate CancerStage IIB Prostate CancerStage III Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

cabazitaxel

Given IV

DRUG

prednisone

Given PO

DRUG

octreotide pamoate

Given IM

OTHER

questionnaire administration

Ancillary studies

DRUG

octreotide acetate

Given SC

Trial Locations (1)

90033

USC/Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

Sanofi
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Sanofi

INDUSTRY

lead

University of Southern California

OTHER

NCT01469338 - Cabazitaxel Plus Prednisone With Octreotide For Castration-Resistant Prostate Cancer (CRPC) Previously Treated With Docetaxel | Biotech Hunter | Biotech Hunter